Leukotriene B
inflammation
leukotriene b4 receptor 1
myocardial infarction
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
07
01
2020
revised:
15
04
2020
accepted:
21
04
2020
pubmed:
10
5
2020
medline:
16
1
2021
entrez:
10
5
2020
Statut:
ppublish
Résumé
Leukotriene B
Identifiants
pubmed: 32385915
doi: 10.1096/fj.202000041R
doi:
Substances chimiques
Ltb4r1 protein, mouse
0
Receptors, Leukotriene B4
0
Leukotriene B4
1HGW4DR56D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8749-8763Informations de copyright
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Roger VL, Go AS, Lloyd-jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2015;125:e2-e220.
Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 1990;82:1147-1159.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4:a006049.
Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161-166.
Yan X, Anzai A, Katsumata Y, et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol. 2013;62:24-35.
Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159-173.
Dick SA, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119:159-176.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1245.
White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372:570-584.
Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest. 2018;128:2691-2701.
Peters-Golden M, Henderson WRJ. Leukotrienes. N Engl J Med. 2007;357:1841-1854.
Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387:620-624.
Riccioni G, Capra V, D’Orazio N, Bucciarelli T, Bazzano LA. Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol. 2008;84:1374-1378.
Rinaldo-Matthis A, Haeggström JZ. Structures and mechanisms of enzymes in the leukotriene cascade. Biochimie. 2010;92:676-681.
Iversen L, Kristensen P, GrØn B, Ziboh VA, Kragballe K. Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. Arch Dermatol Res. 1994;286:261-267.
McGee JE, Fitzpatrick FA. Erythrocyte-neutrophil interactions: formation of leukotriene B4 by transcellular biosynthesis. Proc Natl Acad Sci USA. 1986;83:1349-1353.
Gijón MA, Zarini S, Murphy RC. Biosynthesis of eicosanoids and transcellular metabolism of leukotrienes in murine bone marrow cells. J Lipid Res. 2007;48:716-725.
Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med. 2000;192:433-438.
Miyahara N, Takeda K, Miyahara S, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol. 2005;174:4979-4984.
Terawaki K, Yokomizo T, Nagase T, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol. 2005;175:4217-4225.
Kim ND, Chou RC, Seung E, Tager AM, Luster AD. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med. 2006;203:829-835.
Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:369-375.
Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci USA. 2009;106:21294-21299.
Sasaki F, Koga T, Ohba M, et al. Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models. JCI Insight. 2018;3:1-17.
Matsunobu T, Okuno T, Yokoyama C, Yokomizo T. Thromboxane A synthase-independent production of 12- hydroxyheptadecatrienoic acid, a BLT2 ligand. J Lipid Res. 2013;54:2979-2987.
Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B4receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192:421-431.
Yokomizo T, Kato K, Hagiya H, Izumi T, Shimizu T. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001;276:12454-12459.
Liu J, Wang H, Li J. Inflammation and inflammatory cells in myocardial infarction and reperfusion injury: a double-edged sword. Clin Med Insights Cardiol. 2016;10:79-84.
Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700-714.
Luedde M, Lutz M, Carter N, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling aftermyocardial infarction. Cardiovasc Res. 2014;103:206-216.
Sasaki F, Koga T, Saeki K, et al. Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1. PLoS ONE. 2017;12:1-19.
Kishikawa K, Tateishi N, Maruyama T, Seo R, Toda M, Miyamoto T. ONO-4057, a novel, orally active leukotriene B4 antagonist: Effects on LTB4-induced neutrophil functions. Prostaglandins. 1992;44:261-275.
Noiri E, Yokomizo T, Nakao A, et al. An in vivo approach showing the chemotactic activity of leukotriene B4 in acute renal ischemic-reperfusion injury. Proc Natl Acad Sci USA. 2000;97:823-828.
Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
Blömer N, Pachel C, Hofmann U, et al. 5-Lipoxygenase facilitates healing after myocardial infarction. Basic Res Cardiol. 2013;108:367.
De Hoog VC, Bovens SM, De Jager SCA, et al. BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2015;108:367-376.
Hahn RA, Macdonald BR, Simpson PJ, Potts BD, Parli CJ. Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. J Pharmacol. Exp Ther. 1990;253:58-66.
Gupta K, Phan N, Wang Q, Liu B. Necroptosis in cardiovascular disease-a new therapeutic target. J Mol Cell Cardiol. 2018;118:26-35.
Gurung P, Kanneganti TD. Novel roles for caspase-8 in IL-1β and inflammasome regulation. Am J Pathol. 2015;185:17-25.
Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319-325.
Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316-322.
Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018;175:1377-1400.
Toldo S, Mezzaroma E, Van Tassell BW, et al. Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013;98:734-745.
Sun M, Dawood F, Wen WH, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228.
Bujak M, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57-67.
Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH. Circulation. 2003;107:3133-3140.
Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (vcu-art2) pilot study]. Am J Cardiol. 2013;111:1394-1400.